Table 1 Anti-angiogenic Therapies
From: New therapies for advanced, recurrent, and metastatic endometrial cancers
Study Drug | Target | Prior Lines of Therapy | Patients | ORR | mTTP/PFS (months) | mOS (months) |
|---|---|---|---|---|---|---|
Dalantercept [98] | BMP9/10 | 1–2 | 28 | 0% | 2.1 | 14.5 |
Trebananib [99] | Tie2 Receptor | 1–2 | 32 | 3.1% | 2 | 6.6 |
Cediranib [96] | VEGF/c-kit | 1–2 | 48 | 12.5% | 3.7 | 12.5 |
Sunitinib [91] | VEGF/KIT/PDGFR | ≤ 1 | 33 | 18.2% | 3.0 | 19.4 |
Nintedanib [92] | VEGF/FGFR/PDGFR | 1–2 | 32 | 9.4% | 3.1 | 10.1 |
Lenvatinib [97] | VEGFR/FGFR/RET/KIT/PDGFRβ | 1–2 | 133 | 14.3% | 5.6 | 10.6 |
Aflibercept [95] | VEGFR | 1–2 | 44 | 7% | 2.9 | 14.6 |
Bevacizumab [87] | VEGFR | 1–2 | 52 | 13.5% | 4.2 | 10.6 |
Sorafenib [100] | VEGF/Raf/Ras | ≤ 1 | 39 | 5% | 3.2 | 11.4 |
Thalidomide [101] | VEGFR/bFGF | 1–2 | 21 | 12.5% | 1.7 | 6.3 |